Labiotech.eu

sainsbury john innes centre brassica laboratory crispr

News and Trends 2 Dec 2015

Crops Successfully Edited with CRISPR have no Transgenes! Is this Still GMO?

The CRISPR/Cas9 gene-editing tool is allowing rapid scientific advances in many fields, including human health. Now it has been shown that crop research can also benefit the fight for improved Food Security. Research at the John Innes Centre and the Sainsbury Lab (UK) have successfully edited crops so that future generations of these veggies have […]

December 2, 2015 - 3 minutesmins - By Dani Bancroft

kesios myeloma imperial innovations london

News and Trends 2 Dec 2015

An Imperial College Based Start-Up Has Raised €27M in Series A for a Blood Cancer Drug

Kesios is a start-up Biotech based in London (UK) which has raised over €27M in a Series A funding round for its pipeline targeting the fight against multiple myeloma. A syndicate of UK investors has jumped at the chance to fund this cancer-fighting biotech, whose nuclear factor kappa B (NF-κB)signal pathway targeting pipeline has promise […]

December 2, 2015 - 3 minutesmins - By Dani Bancroft

maurizio montalti bioart synthetic bio biotech

News and Trends 2 Dec 2015

How Can BioArt Help Geneticists and the Biotech Field?

BioArt is a hot interdisciplinary sub-genre springing up in Galleries all over Europe. Here is a summary of a review on the movements increasing relevance to the Biotech Industry… In part thanks to the Biohacking and DIY Biotech movement, accessibility to lab equipment, 3D-printers, and the popularity of the Synthetic Biology iGEM Competition, artists around […]

December 2, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 1 Dec 2015

Rare Diseases: Still a ‘Blue Ocean’ for Biotechs?

We all know the success stories linked to Rare Disease such as Genzyme. But I wanted to get a deeper understanding on what is today considered as Rare disease, who is acting the field and the reasons for so many Biotech companies to dive into the field. Last week was the RARE 2015 congress in […]

December 1, 2015 - 6 minutesmins - By Philip Hemme

amgen leukemia blincyto antibody bispecific

News and Trends 1 Dec 2015

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be granted clinical and regulatory validation so far… After the acquisition in 2012 of Micromet, the Munich-based company that first developed Blinatumomab, Amgen kept revealing the potential of this powerful protein… Blincyto was then approved by the FDA as an orphan […]

December 1, 2015 - 3 minutesmins - By Eva Cosson

lunar esa melissa terraforming ecosystem space

News and Trends 30 Nov 2015

Extra-Terrestrial Ecosystems: The European Space Agency MELiSSA Program

Researching how to bring sustainable life support systems from Earth to the moon or Mars is the first move by the European Space Agency in making Space livable on the longer term scale. Around 25 years ago the MELiSSA project was born…with the aim of easing human exploration of the Solar System, whilst also serving […]

November 30, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 30 Nov 2015

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for their G-protein receptor platform. Heptares Therapeutics was founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), who now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a […]

November 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 30 Nov 2015

How Wearable Electronics Will Change Clinical Trials?

In collaboration with ClinCapture Advances in sensor technology and microelectronics have opened new opportunities in the health and life sciences industries. Wearable sensors allow for continuous bio-monitoring without any manual intervention, thus reducing provider-patient interaction and costs while contributing improvements in the quality of the data. Wearable electronics, or wearables in short, are light electronics with embedded […]

November 30, 2015 - 5 minutesmins - By Glenn Keet

News and Trends 28 Nov 2015

What happened this week? Boston Pharmaceuticals, Biosimilars, Adaptimmune

Monday: First Investment by the Former CEO of Sanofi? Just a €560M Virtual Biotech… #Easy Tuesday: 2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease? Wednesday: Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War! Thursday: A €1.3M Start-Up is Engineering Baker’s Yeast to Make Green House Gases Useful Friday: Could this new […]

November 28, 2015 - 1 minutemin - By Philip Hemme

regeneron sanofi praulant odyssey alirocumab cardiac statins

News and Trends 27 Nov 2015

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

November 27, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 27 Nov 2015

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

Adaptimmune has initiated a phase I/II safety and tolerability study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with non-small cell lung cancer (NSCLC). Adaptimmune is developing the affinity enhanced T-cell therapy targeting the NY-ESO-1 antigen under a collaboration agreement with GlaxoSmithKline (GSK). Located in Oxford (UK) this clinical stage […]

November 27, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Crops Successfully Edited with CRISPR have no Transgenes! Is this Still GMO?

An Imperial College Based Start-Up Has Raised €27M in Series A for a Blood Cancer Drug

How Can BioArt Help Geneticists and the Biotech Field?

Rare Diseases: Still a ‘Blue Ocean’ for Biotechs?

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Extra-Terrestrial Ecosystems: The European Space Agency MELiSSA Program

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

How Wearable Electronics Will Change Clinical Trials?

What happened this week? Boston Pharmaceuticals, Biosimilars, Adaptimmune

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!